Femasys (FEMY) AI Stock Analysis

• Market Cap: $32.06M
• Dividend Yield: N/A
• Average Volume (3M): 414.89K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.32
• Revenue Growth: 15.33%
• EPS Growth: 15.92%
• Country: US
• Employees: 34
• Sector: Healthcare
• Sector Strength: 78
• Industry: Medical Equipment & Supplies
• EPS (TTM): -0.82
• Shares Outstanding: 22,898,468
• 10 Day Avg. Volume: 167,470
• 30 Day Avg. Volume: 414,892
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 27.48
• Price to Cash Flow (P/CF): -1.60
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $12.00
• Price Target Upside: 757.14% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Femasys' stock score is influenced by significant financial performance challenges, including negative profitability and cash flow issues. Technical analysis provides some support with slight upward momentum, although valuation concerns due to negative earnings are notable. Overall, the stock faces considerable risks and requires strategic adjustments to improve its financial health.

Positive Factors

Commercial Partnerships

The partnership with Boston IVF opens up commercial access to 30 fertility centers in the Northeast, and product ordering has already begun.

Efficacy and Safety

FemBloc demonstrated a 0% pregnancy rate across 51 trial participants who met eligibility criteria and achieved confirmed bilateral occlusion three months post-procedure via ultrasound.

Negative Factors

Financial Outlook

Femasys ended 3Q24 with $7.6M in cash and cash equivalents, estimated to fund operations into 2H25.

Femasys Business Overview & Revenue Model

Company Description

Femasys Inc. (FEMY) is a medical device company focused on women's health. The company is dedicated to developing innovative and accessible solutions for women, particularly in the areas of reproductive health and fertility. Its core products and services include non-surgical, in-office technologies designed to address unmet needs in women's healthcare, such as permanent birth control and infertility treatment.

How the Company Makes Money

Femasys generates revenue primarily through the sale of its medical devices and related products. The company's key revenue streams include sales of its proprietary products to healthcare providers and clinics that serve women's health needs. Femasys may also earn income through partnerships with other healthcare companies aimed at distributing or co-developing its technologies. Additionally, the company might receive funding or grants for research and development in the field of women's health, although specific details on such arrangements are not provided.

Femasys Financial Statement Overview

Summary

Femasys shows slight revenue growth but continues to face significant profitability challenges with negative net income, EBIT, and EBITDA margins. The balance sheet indicates a high debt-to-equity ratio, though recent improvements in equity are noted. Negative free and operating cash flow suggest liquidity issues.

Income Statement

The company has shown a slight increase in revenue from $1,071,970 in 2023 to $1,260,643 TTM. However, the net income remains negative, indicating ongoing losses, and the EBIT and EBITDA margins are both negative, reflecting operational challenges. Revenue growth is modest, but profitability remains a significant issue.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio due to negative equity in recent years, though it turned positive in the latest TTM data. This indicates a weak equity position. However, the equity ratio has improved, suggesting a better asset structure. The return on equity remains negative due to persistent net losses.

Cash Flow

The company faces challenges with negative free cash flow and operating cash flow, indicating liquidity issues. Despite a significant increase in financing cash flow, free cash flow remains negative, impacting cash stability. The operating cash flow to net income ratio is less meaningful due to negative figures.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
1.26M	1.07M	1.21M	1.18M	1.04M	929.06K
	Gross Profit
363.82K	691.90K	764.28K	809.30K	731.38K	705.39K
	EBIT
-17.51M	-14.51M	-11.60M	-8.34M	-6.93M	-11.64M
	EBITDA
-15.89M	-13.17M	-10.49M	-6.55M	-5.80M	-10.16M
	Net Income Common Stockholders
-18.10M	-14.25M	-11.39M	-7.54M	-6.91M	-11.27M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
7.41M	21.72M	12.96M	24.78M	3.32M	7.41M
	Total Assets
0.00	27.76M	16.90M	28.58M	7.61M	12.65M
	Total Debt
0.00	6.70M	543.72K	990.21K	2.06M	1.71M
	Net Debt
7.41M	-15.02M	-12.42M	-23.79M	-1.27M	-4.70M
	Total Liabilities
0.00	9.40M	1.65M	2.24M	59.42M	58.02M
	Stockholders Equity
9.97M	18.35M	15.24M	26.33M	-51.82M	-45.37M
Cash Flow		Free Cash Flow
-18.11M	-11.42M	-11.14M	-8.24M	-4.96M	-11.70M
	Operating Cash Flow
-17.41M	-11.28M	-10.73M	-7.93M	-4.93M	-11.01M
	Investing Cash Flow
-782.05K	-143.92K	-407.48K	-306.87K	968.32K	12.32M
	Financing Cash Flow
17.11M	20.18M	-681.64K	29.70M	871.65K	-127.78K

Femasys Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.40
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FEMY, the sentiment is Neutral. The current price of 1.4 is below the 20-day moving average (MA) of 1.52, above the 50-day MA of 1.28, and above the 200-day MA of 1.16, indicating a neutral trend. The MACD of 0.06 indicates Positive momentum. The RSI at 46.95 is Neutral, neither overbought nor oversold. The STOCH value of 19.91 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FEMY.

Femasys Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDXG	70 Outperform	$1.15B	27.38	25.01%	―	8.52%	-32.91%
CTSO	61 Neutral	$54.83M	―	-118.50%	―	1.80%	33.06%
Sector *	49 Neutral	$6.90B	-0.08	-53.01%	2.43%	24.84%	-3.06%
FEMY	45 Neutral	$32.06M	―	-220.59%	―	15.33%	15.92%
VERU	44 Neutral	$73.19M	―	-80.11%	―	-7.43%	69.03%
EVFM	40 Underperform	$830.72K	―	12.00%	―	26.09%	82.19%
HSDT	35 Underperform	$2.46M	―	-259.79%	―	-36.62%	71.25%

Femasys Corporate Events

Femasys Advances in Women’s Health Innovation

Femasys Inc., a pioneering company in women’s reproductive health, is gaining attention with its innovative approach to fertility, contraception, and cancer diagnostics. With a strong focus on providing accessible, in-office solutions, Femasys aims to tap into significant global market opportunities. The company boasts an impressive portfolio, including FDA-cleared products and a robust pipeline. As a woman-led firm, Femasys is well-positioned with a strategic commercial-readiness plan and holds over 180 patents worldwide, drawing interest from investors and stakeholders in the financial markets.